Analysts Anticipate Kodiak Sciences Inc. (NASDAQ:KOD) to Post -$1.61 EPS

Wall Street brokerages expect Kodiak Sciences Inc. (NASDAQ:KODGet Rating) to post ($1.61) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Kodiak Sciences’ earnings, with estimates ranging from ($1.97) to ($0.81). Kodiak Sciences reported earnings per share of ($1.08) in the same quarter last year, which suggests a negative year over year growth rate of 49.1%. The business is expected to report its next earnings report on Monday, January 1st.

On average, analysts expect that Kodiak Sciences will report full year earnings of ($6.64) per share for the current fiscal year, with EPS estimates ranging from ($8.52) to ($3.30). For the next year, analysts expect that the firm will post earnings of ($4.92) per share, with EPS estimates ranging from ($7.74) to ($2.93). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Kodiak Sciences.

Kodiak Sciences (NASDAQ:KODGet Rating) last announced its quarterly earnings results on Tuesday, May 10th. The company reported ($1.83) EPS for the quarter, missing the consensus estimate of ($1.51) by ($0.32). During the same quarter in the previous year, the company earned ($0.98) EPS.

A number of equities research analysts have recently weighed in on KOD shares. Citigroup cut their price objective on Kodiak Sciences from $70.00 to $12.00 and set a “neutral” rating on the stock in a research report on Thursday, February 24th. Barclays dropped their price target on Kodiak Sciences from $81.00 to $50.00 and set an “underweight” rating on the stock in a research report on Monday, February 7th. Truist Financial cut their target price on Kodiak Sciences from $147.00 to $35.00 in a research note on Thursday, February 24th. Roth Capital dropped their price target on shares of Kodiak Sciences from $149.00 to $75.00 in a research note on Monday, February 28th. Finally, The Goldman Sachs Group assumed coverage on shares of Kodiak Sciences in a research note on Friday, February 11th. They set a “buy” rating and a $70.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Kodiak Sciences presently has an average rating of “Hold” and a consensus target price of $45.33.

Shares of NASDAQ KOD traded up $1.19 during midday trading on Tuesday, reaching $9.03. The company had a trading volume of 69,641 shares, compared to its average volume of 1,054,977. The stock has a market cap of $469.11 million, a PE ratio of -1.51 and a beta of 1.97. Kodiak Sciences has a one year low of $4.90 and a one year high of $26.39. The firm’s fifty day moving average price is $6.70 and its 200-day moving average price is $39.15.

In other news, Director Bros. Advisors Lp Baker purchased 223,766 shares of the stock in a transaction dated Wednesday, May 18th. The shares were purchased at an average cost of $5.97 per share, with a total value of $1,335,883.02. Following the acquisition, the director now directly owns 15,142,074 shares of the company’s stock, valued at $90,398,181.78. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last 90 days, insiders have purchased 816,015 shares of company stock worth $5,670,730. 39.70% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its position in Kodiak Sciences by 20.5% in the first quarter. BlackRock Inc. now owns 3,435,960 shares of the company’s stock worth $26,526,000 after purchasing an additional 584,762 shares during the last quarter. Acadian Asset Management LLC bought a new position in shares of Kodiak Sciences in the 1st quarter worth approximately $3,603,000. Krensavage Asset Management LLC purchased a new position in shares of Kodiak Sciences in the first quarter worth approximately $3,479,000. Walleye Capital LLC grew its position in Kodiak Sciences by 1,904.5% during the first quarter. Walleye Capital LLC now owns 356,093 shares of the company’s stock valued at $2,749,000 after buying an additional 338,328 shares during the period. Finally, Graham Capital Management L.P. purchased a new stake in Kodiak Sciences during the first quarter valued at approximately $2,282,000. Institutional investors own 69.80% of the company’s stock.

About Kodiak Sciences (Get Rating)

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.

Read More

Get a free copy of the Zacks research report on Kodiak Sciences (KOD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kodiak Sciences (NASDAQ:KOD)

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.